2024-03-26 14:13:56 ET
Summary
- Neurogene Inc., a clinical-stage company focused on genetic medicines for rare neurological diseases, has seen a significant increase in its share price since joining the Nasdaq in December 2023.
- The company is progressing two drug candidates, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease, with key milestones planned for 2024.
- Neurogene's success will depend on the outcome of its clinical programs and the potential of its proprietary "transgene regulation technology" platform.
Investment Overview
In December last year, Neurogene Inc. ( NGNE ) joined the Nasdaq via a merger with the failing biotech Neoleukin Therapeutics, which had itself gained access to the public markets, via a merger with Aquinox Pharmaceuticals in 2019.
Aquinox - a biotech focused on developing drugs targeting inflammation and hematological cancers - was acquired by Sun Pharmaceuticals subsidiary Taro Pharmaceuticals for just $8.2m in July 2020, while NeoLeukin's drug candidate NL-201, a combined IL-2 and IL-15 agonist, was shelved last year....
Read the full article on Seeking Alpha
For further details see:
Neurogene Stock: Gene Therapy Specialist May Break Chain Of Failed Mergers